Gorlin Syndrome, also known as Nevoid basal cell carcinoma (NBCCS) or Gorlin-–Goltz syndrome, is an infrequent multisystemic disease that is inherited in an autosomal dominant way and shows the high level of penetrance and variable expressiveness. Nevoid basal cell carcinoma syndrome (NBCCS) is known to be a rare autosomal dominantly inherited entity that is characterized most strikingly by the development of cutaneous basal cell carcinomas from an early age, typically puberty, although in some cases, it may occur earlier in childhood. Mutations in the PTCH1 gene cause Gorlin syndrome. This gene provides instructions for making a protein called patched-1, which functions as a receptor.
DelveInsight's "Gorlin Syndrome Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Gorlin Syndrome, historical and forecasted epidemiology as well as the Gorlin Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Gorlin Syndrome Market Key Facts
-
It has also been observed that the estimated prevalence of NBCCS has no observed sex predilection i.e., the male-to-female ratio is 1:1.
-
According to the National Institute of Health (NIH), United States, Gorlin syndrome affects an estimated 1 in 31,000 people. While more than 1 million new cases of basal cell carcinoma are diagnosed each year in the United States, less than 1% of these skin cancers are related to Gorlin syndrome.
-
As per the study conducted by M. Lorenzo et al., “the estimated prevalence of Gorlin Syndrome varies from 1/57,000 to 1/256,000”.
Gorlin Syndrome Market Forecast
The Gorlin Syndrome market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Gorlin Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Gorlin Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Gorlin Syndrome Epidemiology Forecast
The Gorlin Syndrome epidemiology section covers insights about historical and current Gorlin Syndrome patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Gorlin Syndrome Pipeline Analysis and Key Market Players
The Gorlin Syndrome Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gorlin Syndrome market or expected to get launched in the market during the study period. The analysis covers Gorlin Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The pharmaceutical companies in the Gorlin Syndrome market includes:
HedgePath Pharmaceuticals
Mayne Pharma
PellePharm
Leo-Pharma
Phyton Biotech
And many others
For more detailed information on Gorlin Syndrome Market, visit:
https://www.delveinsight.com/report-store/gorlin-syndrome-market